XML 95 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Fair value of financial instruments and marketable securities - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
May 31, 2019
Aug. 23, 2018
Aug. 31, 2015
Financial assets and liabilities measured at fair value on recurring basis              
Realized gain (loss)   $ 0          
Estimated fair value of deferred consideration payable $ 19,300,000 19,300,000   $ 18,300,000      
Deferred consideration payable 19,700,000 19,700,000   19,400,000      
Unrealized Gain (Loss) on Investments   2,529,000 $ 0        
Investment In MRI 6,500,000 6,500,000          
3.00% Convertible senior notes due 2022 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Principal 150,000,000 150,000,000   150,000,000     $ 150,000,000.0
Interest rate ( as a percent )             3.00%
Fair value of convertible notes 156,400,000 156,400,000   146,600,000      
1.50% Convertible senior notes due 2026 | Convertible debt              
Financial assets and liabilities measured at fair value on recurring basis              
Principal $ 287,500,000 $ 287,500,000          
Interest rate ( as a percent ) 1.50% 1.50%          
Fair value of convertible notes $ 273,800,000 $ 273,800,000          
Agilis              
Financial assets and liabilities measured at fair value on recurring basis              
Development milestone payments which the entity is obligated to pay       $ 40,000,000.0   $ 40,000,000.0  
Estimated fair value of deferred consideration payable           $ 38,100,000  
Agilis | Minimum              
Financial assets and liabilities measured at fair value on recurring basis              
Product sales 2.00% 2.00%   2.00%      
Agilis | Maximum              
Financial assets and liabilities measured at fair value on recurring basis              
Product sales 6.00% 6.00%   6.00%      
Development milestone payments which the entity is obligated to pay $ 60,000,000.0 $ 60,000,000.0   $ 60,000,000.0      
Priority review voucher amount   535,000,000.0   535,000,000.0      
Net sales amount 150,000,000.0 150,000,000.0   150,000,000.0      
Non-collaborative Arrangement Transactions | Agilis              
Financial assets and liabilities measured at fair value on recurring basis              
Development milestone payments which the entity is obligated to pay 40,000,000.0 40,000,000.0          
Recurring basis | Total              
Financial assets and liabilities measured at fair value on recurring basis              
Estimated fair value of deferred consideration payable 39,000,000 39,000,000   $ 37,700,000      
Common stock              
Financial assets and liabilities measured at fair value on recurring basis              
Shares owned         $ 4,000,000.0    
Fair value of shares (in dollars per share)         $ 3.10    
Unrealized Gain (Loss) on Investments $ 2,400,000 $ 2,500,000